You are here: Industry Insights > Pharma in China

News List

Research Progress on the Application of Biologics in Childhood Asthma. Xiaomichong
October 30, 2023
Asthma is a heterogeneous, complex chronic disease. Children with severe asthma often experience acute exacerbations, leading to impaired lung function and poor quality of life.
MNC ramps up AI pharmaceutical layout, can AI and pharmaceuticals collide to spark "fireworks"? Yefenghong/PharmaSources
October 27, 2023
AI (Artificial Intelligence) pharmaceuticals refer to the use of artificial intelligence technologies such as big data, cloud computing, and deep learning to assist in drug discovery, drug management, efficacy analysis, and other processes.
Advancements in the field of synthetic biology in 2023 by ChatGPT ChatGPT
October 20, 2023
Synthetic biology is a multidisciplinary field that combines principles from biology, engineering, and computer science to design and construct new biological parts, devices, and systems.
Pharmaceutical Business in China and Worldwide (October)(2023) PharmaSources
November 01, 2023
Pharmaceutical companies sign cooperation agreements with research laboratories to provide commercialization of drug products.
Drug Marketing in China and Worldwide (October)(2023) PharmaSources
November 01, 2023
Drugs have been approved for marketing, and some diseases have been treated.
Pharmaceutical International Cooperation Under the New Drug Policies in China By ChatGPT ChatGPT/PharmaSources
September 11, 2023
The business environment for pharmaceutical companies in China is generally favorable. China has a large population and a growing middle class, which creates a significant demand for healthcare and pharmaceutical products.
Under the new policy tilt, how can MNCs increase their investment in China? Yefenghong/PharmaSources
September 08, 2023
On August 13th, the State Council issued the "Opinions on Further Optimizing the Foreign Investment Environment and Increasing the Attractiveness of Foreign Investment" (hereinafter referred to as the "Opinions").
Chinese Produced ASO Drug Innovation Therapy for Functional Cure of Chronic Hepatitis B Has Obtained FDA Clinical Approval Xiaoyaowan/Pharmasources
September 08, 2023
Recently, Haobo Pharmaceuticals announced that their investigational antisense oligonucleotide (ASO) drug AHB-137 has received clinical trial approval from the FDA in the United States for use in patients with chronic hepatitis B.
Research progress on the biological activity and pharmacological mechanism of naringin Xiaomichong/PharmaSources
September 07, 2023
Naringin is a natural flavonoid compound. It is a colorless needle-shaped crystalline powder that is insoluble in cold water and extremely bitter in taste. Modern pharmacological studies have found that naringin has various therapeutic effects.
Drug Marketing in China and Worldwide (September)(2023) PharmaSources
October 01, 2023
For the importance of disease monoclonal antibodies, the drug ingredient is still being tested.